Point72 Hong Kong LTD Rigel Pharmaceuticals Inc Transaction History

Point72 Hong Kong LTD

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $46,433 - $514,986	42,212 New	42,212 $50,000
Q2 2022 Aug 15, 2022	SELL	$0.67 - $3.19 $3,031 - $14,431	-4,524 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.22 - $3.45 $5,203 - $8,086	-2,344 Reduced 34.13%	4,524 $14,000
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $2,763 - $4,180	-1,171 Reduced 14.57%	6,868 $18,000
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $28,136 - $36,175	8,039 New	8,039 $29,000
Q2 2021 Aug 16, 2021	SELL	$3.09 - $4.54 $4,202 - $6,174	-1,360 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$3.35 - $4.93 $7,172 - $10,555	-2,141 Reduced 61.15%	1,360 $5,000
Q4 2020 Feb 16, 2021	BUY	$2.35 - $3.74 $1,696 - $2,700	722 Added 25.98%	3,501 $12,000
Q3 2020 Nov 16, 2020	BUY	$1.78 - $4.13 $4,946 - $11,477	2,779 New	2,779 $7,000
Q4 2019 Feb 14, 2020	SELL	$1.6 - $2.43 $3,387 - $5,144	-2,117 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$1.63 - $2.62 $3,450 - $5,546	2,117 New	2,117 $4,000
Q3 2018 Nov 14, 2018	SELL	$2.6 - $3.59 $767 - $1,059	-295 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $834 - $1,212	295 New	295 $1,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.84B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.